The current role of BTK inhibitors in the treatment of Waldenstrom’s Macroglobulinemia
Article 2020 en
Authors
MG
Maria Gavriatopoulou
DF
Despina Fotiou
IN
Ioannis Ntanasis‐Stathopoulos
Abstract
1 min read
The optimal therapeutic approach for WM patients remains to be established. The question of whether a combinatory (or synergistic) regimen to overcome resistance and allow for a fixed treatment duration will allow for deep and durable response is being addressed in ongoing clinical trials.
Discussion(0)
No comments yet. Be the first to comment.